Jpmorgan Chase & CO Angion Biomedica Corp. Transaction History

Jpmorgan Chase & CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.1 - $2.23 $156,032 - $316,321	-141,848 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$1.72 - $2.96 $5,768 - $9,927	-3,354 Reduced 2.31%	141,848 $300,000
Q4 2021 Feb 10, 2022	SELL	$2.35 - $9.95 $12,455 - $52,734	-5,300 Reduced 3.52%	145,202 $421,000
Q3 2021 Nov 12, 2021	BUY	$9.31 - $13.25 $1.4 Million - $1.99 Million	150,502 New	150,502 $1.47 Million

Ticker ANGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,113,300
Description
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primaril...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.